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reated on July 1, 2000, the Department of Managed Health Care (DMHC) 
regulates the managed care industry in California. The creation of DMHC 
resulted from Governor Gray Davis’s approval of AB 78 (Gallegos) (Chapter 
525, Statutes of 1999), a bill that reformed the regulation of managed care in 
the state. DMHC is created in Health and Safety Code section 1341; DMHC’s regulations are 
codified in Title 28 of the California Code of Regulations (CCR). 
DMHC administers the Knox-Keene Health Care Service Plan Act of 1975, Health and 
Safety Code section 1340 et seq., which is intended to promote the delivery of health and medical 
care to Californians who enroll in services provided by a health care service plan. A “health care 
service plan” (health plan)—more commonly known as a health maintenance organization (HMO) 
or managed care organization (MCO)—is defined broadly as any person who undertakes to arrange 
for the provision of health care services to enrollees, or to pay for or reimburse any part of the cost 
for those services, in return for a prepaid or periodic charge paid by or on behalf of the enrollees.  
In Health and Safety Code section 1342, the legislature has expressly instructed the 
Department Director to ensure the continued role of the professional as the determiner of the 
patient’s health needs; ensure that enrollees1 are educated and informed of the benefits and services 
available in increase consumer choice in the healthcare market; and promote effective 
representation of the interests of enrollees, including ensuring the best possible health care at the 
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lowest possible cost by transferring financial risk of health care from patients to providers. The 
Department Director must also prosecute individuals and/or health plans who engage in fraud or 
misrepresent or deceive consumers; and ensure the financial stability of health plans through 
proper regulation health care must be accessible to enrollees and rendered in a manner to provide 
continuity of care, which includes a grievance process that is expeditious and thoroughly reviewed 
by DMHC. 
The Director of DMHC is appointed by, and serves at the pleasure of, the Governor. The 
Department’s staff of attorneys, financial examiners, health plan analysts, physicians, health care 
professionals, consumer service representatives, and support staff assist the DMHC Director in 
licensing and regulating more than 130 health plans in California. Licensed health plans include 
HMOs and other full-service health plans, as well as several categories of specialized health plans 
such as prepaid dental, vision, mental health, chiropractic, and pharmacy plans. DMHC-licensed 
health plans provide health care services to approximately 26 million California enrollees. 
Created in Health and Safety Code section 1374.30 et seq., DMHC’s independent medical 
review (IMR) system allows health plan enrollees to seek an independent review when medical 
services are denied, delayed, or otherwise limited by a plan or one of its contracting providers, 
based on a finding that the service is not medically necessary or appropriate. The independent 
reviews are conducted by expert medical organizations that are independent of the health plans 
and certified by an accrediting organization. An IMR determination is binding on the health plan, 
and the Department will enforce it. 
SB 260 (Speier) (Chapter 529, Statutes of 1999), added section 1347.15 to the Health and 
Safety Code to create the Financial Solvency Standards Board (FSSB). Comprised of the DMHC 
Director and seven members appointed by the Director, FSSB periodically monitors and reports 
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on the implementation and results of those requirements and standards, and reviews proposed 
regulatory changes. FSSB advises the DMHC Director on matters of financial solvency affecting 
the delivery of health care services. FSSB develops and recommends financial solvency 
requirements and standards relating to plan operations.  
DMHC houses the Help Center, which is open 24 hours a day, 365 days a year, and 
functions in many languages to help consumers who experience problems with their health plan. 
The Help Center educates consumers about their health care rights; resolves consumer complaints; 
helps consumers navigate and understand their coverage; and ensures access to appropriate health 
care services. The DMHC Help Center provides direct assistance to health care consumers through 
a call center and online access. DMHC is funded by assessments on its regulated health plans. 
MAJOR PROJECTS 
DMHC Rulemaking 
The following are status updates on recent rulemaking proceedings that DMHC has 
initiated, some of which were covered in more detail in Volume 24, Number 1 of the California 
Regulatory Law Reporter [24:1 CRLR 20–26]:  
♦ General Licensure Requirements.  On November 30, 2018, DMHC published a notice 
of 4th comment period to add section 1300.49, Title 28 of the CCR, which attempted to clarify the 
Knox-Keene Act’s definition of a “health care service plan” that requires licensure by DMHC. The 
new regulation would have defined “health care service plan” to include an entity that takes on 
global risk (both institutional and professional risk) for services provided to health plan enrollees, 
would have set forth requirements for a restricted health plan license, as well as standards for 
obtaining an exemption from licensing requirements. The modified text is the result of information 
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received during the third comment period and the information in the Notice of Disapproval issued 
by the Office of Administrative Law (OAL) on October 8, 2018, and in its Decision of Regulatory 
Action dated October 15, 2018, which is set forth in the proposed language. [24:1 CRLR 20–21] 
According to the final statement of reasons and its attached addendum, the proposed 
regulation updates the Economic Impact Analysis by providing clarity around licensure 
requirements of restricted health care service plans; specifies existing state law for health care 
service plans; simplifies the information the Director will consider when determining whether an 
exemption request will be granted; and identifies a process for an exemption request from DMHC.  
On March 5, 2019, OAL approved the final text of the general licensure requirements to 
be effective July 1, 2019.   
♦ Cancellations, Rescissions, and Non-renewals of Health Plan Enrollment, 
Subscription, or Contract. On December 28, 2018, DMHC published a notice of 2nd comment 
period to delete sections 1300.65, 1300.65.1, 1300.65.2, and add sections 1300.65, 1300.65.1, 
1300.65.2, 1300.65.3, 1300.65.4, 1300.65.5, Title 28 of the CCR, to clarify and interpret the 
rights and responsibilities of plans, providers, and enrollees prior to, during, and following 
cancellations, rescissions, or non-renewals of an enrollee’s health care coverage. The modified 
text is the result of information received during the initial comment period, which is set forth in 
the proposed language. 
On February 28, 2019, DMHC published a notice of 3rd comment period affecting the 
same sections outlined in the prior paragraph. The revised language responds to public comments 
to clarify and keep consistency in the relevant terms throughout the regulation. 
On June 22, 2018, DMHC originally proposed amendments to the Cancellations, 
Rescissions, and Nonrenewals regulations, in order to impose limitations on the cancellation, 
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rescission, and nonrenewal of health care service plan contracts, and provide enrollees, 
subscribers, and group contract holders with a right to file a grievance with DMHC in certain 
situations consistent with federal law under the Patient Protection and Affordable Care Act 
(PPACA). [24:1 CRLR 22–23] 
DMHC did not schedule a public hearing on these proposed regulatory changes, but 
accepted written comments until March 15, 2019. At this writing, DMHC is reviewing the 
comments received during the comment period and is preparing modified text of the proposed 
changes. 
♦ Financial Solvency of Risk-Bearing Organizations (RBOs). DMHC does not directly 
regulate RBOs; however, it is authorized to regulate health plan contracts with RBOs. Hence, on 
May 25, 2018, DMHC originally proposed amendments to the Financial Solvency of RBOs 
regulation in a notice of proposed rulemaking. [24:1 CRLR 23–25] On November 15, 2018, 
DMHC published a notice of 3rd comment period to amend sections 1300.75.4, 1300.75.4.1, 
1300.75.4.2, 1300.75.4.5, 1300.75.4.7, 1300.75.4.8, and 1300.76, Title 28 of the CCR, for an 
additional 15-day public comment period that ended on December 4, 2018. The third revision of 
the modified text addresses public comments received during the second comment period.  
On January 4, 2019, DMHC published a notice of 4th comment period to continue 
amending the same sections outlined in the prior paragraph, for an additional 15-day public 
comment period that ended on January 22, 2019. The fourth revision of the text is a result of the 
information received during the third comment period, which is set forth in the proposed language, 
which is the final text submitted to OAL. According to the final statement of reasons, the proposed 
regulations represent the cumulative effort of DMHC to adopt rules and regulations to implement 
a process for reviewing and grading the financial solvency of RBOs. This includes clarifying the 
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financial information required from RBOs to assist in DMHC’s review, including when DMHC 
conducts audits and when DMHC processes corrective action plans for RBOs with solvency 
problems. The regulations cover disclosure of relevant information from health plans to RBOs to 
enable the organization to be informed regarding the risks assumed under the parties’ contract. The 
regulations also cover how health plans and RBOs file periodic reports to DMHC, ensuring 
confidentiality of consumers.  
At its April 10, 2019 teleconference meeting, DMHC voted to adopt the final text of the 
regulatory action, until such time as OAL approves the regulatory action through the formal 
rulemaking process. A hearing on the proposed regulations is set for May 6, 2019.  
Standard Prescription Drug Formulary Template  
On February 20, 2019, DMHC published a notice of 2nd comment period to add section 
1300.67.205, Title 28 of the CCR, a proposed regulatory action to set minimum standards for its 
drug formulary. The modified text is the result of comments received during the initial 45-day 
comment period that ended on November 13, 2018, and the public hearing held on November 13, 
2018. DMHC accepted written comments relating to the modified text until March 7, 2019. 
Following the second comment period, DMHC released the revised text of the proposed regulation. 
At the time of this writing, DMHC had not scheduled a public hearing on the proposed changes 
and was reviewing additional comments.  
DMHC also released an addendum to the Notice of Rulemaking and the Initial Statement 
of Reasons noticed on September 28, 2018. [24:1 CRLR 21–22] In the addendum, DMHC updated 
its Summary of Fiscal Impact contained in its initial Notice of Rulemaking, to now include the 
determination that there will be a fiscal impact to Medi-Cal only managed care plans to comply 
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with the requirements of the regulation. The estimated fiscal amount to upgrade computer systems 
is $13,041 per health plan, bringing the total fiscal impact to $143,452. At this writing, DMHC 
has not taken further action on the regulation.  
DMHC Releases 2017 Timely Access Report 
On December 19, 2018, DMHC published the Timely Access Report for Measurement 
Year (MY) 2017. The Timely Access Regulation, which became effective in 2010, “requires that 
health plan networks be sufficient to meet a set of standards, which include specific timeframes 
under which enrollees must be able to obtain care.” The Timely Access Report summarizes 
provider appointment availability data that health plans submitted to DMHC for Measurement 
Year 2017. The charts within the report show provider responses to appointment availability 
requests.  
According to the report, DMHC required full-service health and behavioral health plans to 
utilize external vendors to validate the health plans’ Timely Access data prior to submitting them 
to DMHC. DMHC found some data errors in MY 2017 data that health plans were unable to 
correct. Although these errors limit some of the possible data representations, DMHC was able to 
compare MY 2017 data across health plans at a more granular level than for previously reported 
years. As a result, DMHC expanded the number of charts in the report and displayed data by type 
of health plan for the first time: Commercial; Individual/Family; and Medi-Cal.  
Regarding 2017 data, some health plans continued to have issues with following the 
mandatory methodology, completing all of the required surveys, and achieving an acceptable 
statistical sample of surveyed providers. According to DMHC, ensuring that health plans provide 
timely access to health care services is one of its highest priorities and DMHC continues to work 
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with stakeholders, including health plans, providers, associations and consumer advocates to refine 
the provider survey methodology and develop an acceptable rate of compliance for provider 
appointment wait times. Furthermore, DMHC is taking the necessary steps to have mandatory 
methodologies for measuring compliance with the timely access standards and the acceptable rate 
of compliance included in regulation so that compliance results are comparable year over year. 
Key Survey Findings for Full-Service Health Plans. The percentage of all surveyed 
providers who had appointments available within the wait time standards (urgent and non-urgent) 
ranged from a high of 99% to a low of 63% (Chart 1). For non-urgent appointments, the percentage 
of all surveyed providers who had appointments available within the wait time standards ranged 
from a high of 99% to a low of 70% (Chart 5).  For urgent appointments, the percentage of all 
surveyed providers who had appointments available within the wait time standards ranged from a 
high of 99% to a low of 52% (Chart 9).  
Key Survey Findings for Behavioral Health Plans.  The percentage of all surveyed 
providers who had appointments available within the wait time standards (urgent and non-urgent) 
ranged from a high of 83% to a low of 64% (Chart 13). For non-urgent appointments, the 
percentage of all surveyed providers who had appointments available within the wait time 
standards ranged from a high of 87% to a low of 71% (Chart 17). For urgent appointments, the 
percentage of all surveyed providers who had appointments available within the wait time 
standards ranged from a high of 80% to a low of 57% percent (Chart 21). 
Key Audit Findings for Full-Service Health Plan, Kaiser Permanente. The percentage of 
all audited providers meeting appointment wait time standards across all provider types and 
appointment types (urgent and non-urgent) was 92% (Chart 25). The percentage of all audited 
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providers meeting non-urgent appointment standards was 91% (Chart 29). The percentage of all 
audited providers meeting urgent appointment standards was 98% (Chart 33).  
DMHC Releases 2017 Prescription Drug Cost 
Transparency Report 
Despite undecided legal challenges to the constitutionality of the 2017 legislation [see 
LITIGATION], on December 27, 2018, DMHC released its Prescription Drug Cost Transparency 
Report (SB 17). SB 17 (Hernandez) (Chapter 603, Statutes of 2017), as codified in Health and 
Safety Code section 1367.243, requires health plans that file rate information with DMHC to 
annually report specific information related to the costs of covered prescription drugs. Prescription 
drug data was submitted by 25 health plans for measurement year 2017. DMHC states that it will 
continue to collect and report on the data required by SB 17, which will enable the public to 
understand how prescription drugs impact health care premiums over time. 
This report looks at the impact of the cost of prescription drugs on health plan premiums.  
According to the report, DMHC considered the total volume of prescription drugs prescribed by 
health plans and the total cost paid by health plans for these drugs, on both an aggregate spending 
level and a per member per month basis (PMPM). DMHC also analyzed how the 25 most 
frequently prescribed drugs, the 25 most costly drugs, and the 25 drugs with the highest year-over-
year increase in total annual spending impacted premiums.  
Key Findings. According to the report, health plans paid nearly $8.7 billion for prescription 
drugs in 2017. Prescription drugs accounted for 13.1% of total health plan premiums. Health plans’ 
prescription drug costs increased by 5% in 2017, whereas medical expenses increased by 5.9%. 
Overall, total health plan premiums increased 4.8% from 2016 to 2017. Manufacturer drug rebates 
equaled approximately $915 million, or about 10.5%, of the $8.7 billion spent on prescription 
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drugs. While specialty drugs accounted for only 1.6% of all prescription drugs, they accounted for 
over half (51.5%) of total annual spending on prescription drugs. Generic drugs accounted for 
nearly 90% (87.8%) of all prescribed drugs but only 23.6% of the total annual spending on 
prescription drugs. Brand name drugs accounted for 10.6% of prescriptions and constituted 24.8% 
of the total annual spending on prescription drugs. The 25 Most Frequently Prescribed Drugs 
represented 47.7% of all drugs prescribed and approximately 42.8% of the total annual spending 
on prescription drugs. For the 25 Most Frequently Prescribed Drugs, enrollees paid approximately 
3% of the cost of specialty drugs and over half (56.6%) the cost of generic drugs. Overall, plans 
paid over 90% of the cost of the 25 Most Costly Drugs across the three categories (generic, brand 
name, and specialty). 
As reported by DMHC, the impact of prescription drug costs on health plan premiums is 
significant. Health plans paid nearly $8.7 billion for prescription drugs in 2017, which accounted 
for 13.1% of the total health plan premium in 2017. This amount is primarily related to the cost of 
specialty drugs. Overall, specialty drugs accounted for just over 1% of the total number of drugs 
prescribed, and represented over half of the health plans’ total annual spending on prescription 
drugs. Generic drugs made up nearly 90% at of all the drugs prescribed in 2017 but represented 
only about one-quarter of total annual spending on prescription drugs. 
Recent Enforcement Actions 
Following are recent enforcement actions taken by DMHC:  
♦ DMHC Approves Optum’s Acquisition of DaVita. On November 28, 2018, DMHC 
approved Optum, Inc.’s acquisition of DaVita Health Plan of California, as contained in a 
document setting forth the conditions of the merger. DMHC’s approval includes several conditions 
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that will protect enrollees and support behavioral health services. Optum and DaVita agree to not 
increase premiums as a result of acquisition costs, and keep premium rate increases to a minimum. 
The plans also agree to invest at least $58 million in California as follows: (1) $40 million in 
philanthropic activities in California; (2) $10 million to one or more areas that include support for 
scholarships through the United Health Foundation Diverse Scholars Initiative, medical grants for 
California families, investments to help address social determinants of health and other health and 
wellness initiatives; and (3) $8 million to support behavioral health services by providing 
scholarships to those seeking to become a psychiatrist or psychiatric nurse practitioner in the field 
of Child and Adolescent psychiatry. The health plans will also support activities and implement 
programs to address the opioid crisis. This includes educating providers on substance abuse 
detection and prescribing naloxone and buprenorphine.  
According to DMHC Director Rouillard, there has been rapid consolidation in the health 
care industry, including health plan mergers, and “[a]s the primary state regulator of health plans, 
[DMHC’s] job is to protect the health care rights of impacted enrollees and ensure a stable health 
care delivery system.” In response to DaVita’s notice of the proposed acquisition by Optum in 
early 2018, DMHC conducted a comprehensive review of the transaction to ensure compliance 
with the Knox-Keene Act. DMHC examined both parties’ organization and corporate structures, 
administrative capacity changes, health care delivery system changes, product or subscriber 
changes, the effect of the transaction on the financial viability of DHMC licensed plans, the 
financing for the transaction, and its impact on consumers. DMHC’s Financial Solvency Standards 
Board (FSSB) held a public meeting on the acquisition back in April, 2018. At the meeting, 
Director Rouillard reiterated that the Department’s primary focus in reviewing these mergers is to 
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ensure compliance with the strong consumer protections and financial solvency requirements of 
the Knox-Keene Act.  
♦ LA Care Grievance Process Violations Result in $280,000 Fine. On November 6, 2018, 
DMHC announced it would fine LA Care $280,000 for systemic grievance process violations. 
DMHC Director Rouillard stated that health plans are required by law to have a grievance process 
in place to resolve consumers’ complaints and ensure access to appropriate care. DMHC found 
that “LA Care failed to comply with laws surrounding the grievance and appeals system and must 
correct their deficiencies to ensure consumers know their health care rights and how to act on 
them.” 
According to DMHC, this enforcement action is a result of 21 cases involving 63 consumer 
grievance violations that occurred during 2014 through 2017. In these cases, LA Care deprived 
enrollees of their rights to medical care in that it failed to identify, timely process, and resolve 
consumer grievances. Additionally, LA Care did not comply with statutory timeframes to provide 
DMHC information during investigation of member complaints. The plan has acknowledged its 
failure to comply with the law, and DMHC has determined that an administrative penalty and 
Corrective Action Plan are warranted. The corrective actions include employee training and 
increased oversight of the grievance and appeals system. 
DMHC Approves CVS-Aetna Merger 
On November 15, 2018, DMHC Director Rouillard issued a statement of approval for the 
CVS-Aetna merger. DMHC placed conditions on the approval of the merger. CVS and Aetna 
agreed to not increase premiums as a result of acquisition costs and to keep premium rate increases 
to a minimum. The plans also agree to invest nearly $240 million in California’s health care 
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delivery system. As part of DMHC’s conditions, CVS and Aetna confirmed the sale of Aetna’s 
Medicare Part D Individual Prescription Drug business to WellCare in compliance with the 
conditional approval by the U.S. Department of Justice. Additionally, until the divestiture is 
completed, CVS and Aetna will guarantee Aetna’s Medicare Part D Individual Prescription Drug 
business in California continues to be a viable and competitive plan for 2019.  
On April 5, 2019, Judge Richard Leon of the U.S. District Court for the District of 
Columbia heard argument from parties as to what, if any, witnesses should be called at any hearing 
on the Government’s Motion for Entry of Final Judgment. Pending Judge Leon’s approval, CVS 
agreed to temporarily allow Aetna to independently make critical product, pricing and personnel 
decisions.  
Prior editions of the Reporter have covered the proposed acquisition in January of 2018, 
through DMHC’s examination of CVS’ and Aetna’s structures, including a public hearing in May 
of 2018. [23:2 CRLR 18–19] On October 10, 2018, the Department of Justice conditionally 
approved the CVS-Aetna merger. [24:1 CRLR 27–28] 
DMHC Approves Cigna-Express Scripts Merger 
On December 13, 2018, the Cigna-Express merger was approved by the New York 
Department of Financial Services and DMHC. Further, the New York Superintendent, Maria 
Vullo, cancelled the hearing that was scheduled for January 10, 2019 after receiving commitments 
from the applicants to conditions of approval that address anti-competitive concerns.  
On December 13, 2018, Director of DMHC Rouillard issued a statement of approval for 
the Cigna-Express acquisition. DMHC placed conditions on the approval of the merger, including 
agreement to not increase premiums as a result of acquisition costs and to keep premium rate 
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increases to a minimum. Both companies will also invest over $60 million in California healthcare 
initiatives, including the opioid crisis and healthcare delivery.  
The U.S. Department of Justice approved the Cigna-Express acquisition in September of 
2018. [24:1 CRLR 28–29] 
LEGISLATION 
AB 1802 (Committee on Health), as amended April 11, 2019, would amend sections 
1358.20, 1368.015, 1368.02, 1371, and 1373.65 of the Health and Safety Code, relating to health 
care service plans. The bill would clarify that the obligation of a health plan to comply with claims 
reimbursement obligations is not deemed to be waived if the plan requires its medical groups, 
independent practice associations, or other contracting entities to pay claims for covered services. 
According to the Committee on Health, this bill reverts language back to its original statutory 
language to apply to all health plans and updates DMHC telephone and internet website addresses 
in specified materials. [A. Health] 
AB 1174 (Wood), as amended March 25, 2019, would add sections 1341.46 and 1371.32 
to the Health and Safety Code, relating to anesthesia services. According to the author, this bill 
would ensure that health plans and health insurers have a contractual relationship with 
anesthesiologists such that enrollees will have access to these types of providers at contracted 
facilities. This bill would require a health plan to notify DMHC before the expiration or termination 
of an anesthesia services contract. This bill would also require DMHC to make a finding that the 
health plan have contracts in place that meet the following: 1) the health plan has a contract with 
at least one individual health professional who is licensed by the state to deliver or furnish 
anesthesia services (individual health professional) for each of its contracted facilities; and 2) an 
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enrollee requiring anesthesia services has access to contracted individual health professional at all 
times and for all procedures at each of the contracted facilities. [A. Appr] 
AB 651 (Grayson), as amended April 8, 2019, would add section 1371.55 to the Health 
and Safety Code, relating to air ambulance services. This bill would require a health plan contract 
to provide that if an enrollee receives covered services from a noncontracting air ambulance 
provider, the individual would pay no more than the same cost sharing that the individual would 
pay for the same covered services received from a contracting air ambulance provider, as specified. 
Among other things this bill would, commencing January 1, 2020, and to the extent that federal 
financial participation is available and federal approvals have been obtained, require the 
department to set and maintain the Medi-Cal fee rate for air ambulance services provided by either 
fixed or rotary wing aircraft that is equal to a percentage of the rural Medicare rates for those 
services. This would be a rate increase for air ambulance providers that, according to the sponsor, 
is necessary to maintain adequate coverage of services across the state. [A. Health]  
AB 1611 (Chiu), as introduced February 22, 2019, would amend section 1317.2a of, and 
add sections 1317.11, 1317.12, 1371.6, 1371.7, and 1385.035 to, the Health and Safety Code, 
relating to hospital service costs. This bill would prohibit a hospital from charging more than the 
greater of the average contracted rate or 150% of the amount Medicare reimburses on a fee for 
service basis for the same or similar hospital services in the general geographic region in which 
the services were rendered, as specified, for emergency care or post-stabilization care. This bill 
would also require a health plan contract amended or renewed on or after January 1, 2020, to 
provide that if an enrollee receives covered services from a noncontracting hospital, the enrollee 
is prohibited from paying more than the same cost sharing that the enrollee would pay for the same 
covered services received from a contracting hospital. [A. Health] 
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AB 1670 (Holden), as amended March 18, 2019, would add section 1371.85 to the Health 
and Safety Code, relating to health care coverage. This bill would authorize a provider that 
contracts with a health plan to bill an enrollee for a service that is not a covered benefit if the 
enrollee consents in writing and that written consent meets specified criteria. The bill would 
require a contracting provider to provide an enrollee with a written estimate of the person’s total 
cost, based on the standard rate the provider would charge for the service, if the service sought is 
not a covered benefit under the person’s health plan. The bill would require these documents to be 
in the language spoken by the enrollee as specified. A willful violation of the bill’s requirements 
relative to health plans would be a crime. [A. Health] 
AB 744 (Aguiar-Curry), as introduced February 19, 2019, would amend section 2290.5 
of the Business and Professions Code, and amend section 1374.13 of, and add section 1374.14 to 
the Health and Safety Code, relating to health care coverage. This bill would require a contract 
between a health plan and a healthcare provider to specify that the health plan reimburse a 
healthcare provider for the diagnosis, consultation, or treatment of an enrollee, delivered through 
telehealth services on the same basis and to the same extent that the health plan is responsible for 
reimbursement for the same service through in-person diagnosis, consultation, or treatment. [A. 
Health] 
AB 954 (Wood), as amended March 27, 2019, would add section 1374.193 to the Health 
and Safety Code, relating to dental services. According to the author, network leasing 
arrangements present numerous problems for dentists and their patients because plans that lease 
or purchase networks do not have any responsibility to be transparent about which fee schedules 
are in effect for their patients. To address the need for transparency, the bill would authorize a 
health plan that issues, sells, renews, or offers a contract covering dental services to grant third 
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party access to a provider network contract entered into, amended, or renewed on or after January 
1, 2020, or access to services or discounts provided pursuant to that provider network contract if 
certain criteria are met. [A. Appr] 
AB 767 (Wicks), as amended April 9, 2019, would amend section 1374.55 of the Health 
and Safety Code, relating to infertility. Requires every health plan contract policy that is issued, 
amended, or renewed on or after January 1, 2020, to provide coverage for in vitro fertilization 
(IVF), as a treatment of infertility, and mature oocyte cryopreservation (OC). This bill would delete 
the exemption for religiously affiliated employers and health plans, from the requirements relating 
to coverage for the treatment of infertility, thereby imposing these requirements on these 
employers and plans. This bill would also delete the requirement that a health plan contract provide 
infertility treatment under agreed upon terms that are communicated to all group contractholders 
and prospective group contractholders. [A. Health] 
SB 600 (Portantino), as introduced February 22, 2019, would add section 1374.551 to the 
Health and Safety Code, relating to fertility preservation. This bill would clarify that a health plan 
contract that covers hospital, medical, or surgical expenses include coverage for standard fertility 
preservation services when a medically necessary treatment may cause infertility to an enrollee. 
This bill would also prohibit a health plan from denying coverage of standard fertility preservation 
services based on medical necessity of an enrollee’s treatment plan, as specified. As outlined in 
the Bill Analysis, “DMHC has initiated enforcement action, and DMHC no longer approves plan 
documentation that purports to exclude medically necessary fertility preservation. DMHC has 
communicated this to health plans and has conducted individual plan-by-plan conferences to 
explain DMHC’s position and expectation for compliance.” [S. Health] 
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SB 163 (Portantino), as amended April 9, 2019, would amend section 1374.73 of the 
Health and Safety Code, to expand the definition of behavioral health treatment (BHT) and expand 
the provider qualifications to include more provider types that can provide BHT under the mandate 
that health plans and insurers cover BHT for pervasive developmental disorder or autism. The bill 
would prohibit the setting, location, or time of treatment recommended by a qualified autism 
services provider from being used as the only reason to deny or reduce coverage for medically 
necessary services, and requires the setting be consistent with the standard of care for BHT. This 
bill would also require the intervention plan designed by the qualified autism service provider, 
when clinically appropriate, to include parent or caregiver participation that is individualized to 
the patient and takes into account the ability of the parent or caregiver to participate in therapy 
sessions and other recommended activities. Notably, the bill would bring health plans in the Medi-
Cal program into compliance with the Mental Health Parity and Addiction Equity Act of 2008 
(MHPAEA). [S. HumanS] 
SB 11 (Beall), as introduced December 3, 2018, would add sections 1374.77 and 1374.78 
to the Health and Safety Code, to require a health plan to submit an annual report to DMHC, 
certifying compliance with state and federal mental health parity laws, as specified. The bill would 
require DMHC to review the reports submitted by health plans to ensure compliance with relevant 
laws, and would require DMHC to make the reports and the results of the reviews available 
publicly, including posting on its website. The bill would also require the California State Auditor 
to review DMHC and the Department of Insurance’s implementation of this bill and report its 
findings to the Legislature. The addition of section 1374.78 would prohibit prior authorization or 
step therapy requirements on any prescription medication approved by the federal Food and Drug 
Administration for the treatment of substance use disorders. [S. Health] 
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AB 731 (Kalra), as amended March 20, 2019, would amend sections 1385.01, 1385.02, 
1385.03, and 1385.07 of the Health and Safety Code, relating to DMHC’s rate review of health 
plans. According to the author, “[m]any [consumers] are struggling with ever rising co-pays and 
health insurance premiums that have risen 249% since 2002, more than six times the increase in 
the state’s overall inflation.” This bill would expand the existing requirement—that health plans 
offering a contract or policy in the individual or small group market file specified information with 
DMHC—to apply to large group health plan contracts. The bill would require a plan to disclose 
specified information by geographic region, including annual medical trend factor assumptions by 
aggregate benefit category and the top 25 procedures in each benefit category. This bill would also 
require a health plan that fails to provide all the information required, to be determined an 
unjustified rate. To effectuate its purpose, the bill would eliminate confidentiality protections for 
contracted rates between a health plan and a large group. [A. Appr]  
AB 1309 (Bauer-Kahan), as introduced February 22, 2019, would add section 1399.848 
to the Health and Safety Code, to require a health plan, for policy years beginning on or after 
January 1, 2020, to provide a special enrollment period to allow individuals to enroll in individual 
health benefits plans through the Exchange from December 16 of the preceding calendar year, to 
January 31 of the benefit year. The bill would also require, for health plans offered outside of the 
Exchange, that the annual open enrollment period for policy years beginning on or after January 
1, 2020, extend from October 15 of the preceding calendar year, to January 31 of the benefit year. 
[A. Appr] 
SB 159 (Weiner), as amended April 11, 2019, would add section 1342.74 to the Health 
and Safety Code, to preclude health plans from requiring a prior authorization or step therapy for 
combination antiretroviral drug treatments that are medically necessary for the prevention of 
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AIDS/HIV, including pre-exposure prophylaxis or post-exposure prophylaxis. This bill would also 
require Medi-Cal to reimburse pharmacies for initiating and furnishing pre-exposure prophylaxis 
or post-exposure prophylaxis, and permits a pharmacist to furnish these treatments in accordance 
with protocols established by the bill. According to the author, allowing pharmacists to furnish 
these treatments without a prescription “will expand access, help increase the number of 
individuals who use these HIV preventatives, and will help California achieve its goal to end new 
HIV infections.” [S. Health] 
AB 1249 (Maienschein), as amended March 18, 2019, would add and repeal section 
1343.3 to the Health and Safety Code, to require the DMHC Director, by May 1, 2020, to authorize 
two pilot programs, one in northern California and one in southern California. The purpose of the 
pilot programs is to demonstrate the control of costs for health care services and the improvement 
of health outcomes and quality of service when compared against a sole fee-for-service provider 
reimbursement model. Each pilot program would be conducted under the voluntary employees’ 
beneficiary association (VEBA) with more than 100,000 enrollees. The bill would further require 
each health care provider participating in a pilot program to report to DMHC with information 
regarding cost savings and clinical patient outcomes. New section 1343.3 would require the 
DMHC to report those findings to the legislature by June 1, 2026. [A. Health] 
SB 612 (Pan), as introduced on February 22, 2019, would add section 1348.7 to the Health 
and Safety Code, to require health plans, health insurers, and medical groups, on or before January 
1, 2021, to annually report to the Office of Statewide Health Planning and Development (OSHPD) 
in its participation in a list of health care programs and activities. New section 1348.7 would create 
requirements for the data that needs to be included, such as detailed descriptions of enrollees, 
demographic profiles, numbers and types of participating providers, lengths of participation of 
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enrollees, lengths of carrier participation, and performance measures and outcomes. According to 
the author, “[t]his bill provides baseline data to policymakers, purchasers, and the public on the 
extent to which health plans, health insurers, and medical groups are participating in activities that 
provide high quality care and improve outcomes for Californians with chronic disease.” [S. Appr] 
SB 129 (Pan), as amended on February 26, 2019, would amend section 1348.95 of the 
Health and Safety Code, to require health plans and insurers to annually report enrollment data for 
products sold inside and outside of Covered California, any other business lines, and multiple 
employer welfare arrangements. New section 1348.95 would require DMHC to publicly report 
annual enrollment data no later than April 15 of each year. According to the author, this bill is 
necessary to update the annual health plan and insurer enrollment reporting requirements that are 
required under the Affordable Care Act. [S. Appr] 
SB 406 (Pan), as introduced on February 20, 2019, would amend section 1348.96 of the 
Health and Safety Code, to require DMHC (and the Department of Insurance) to each prepare, in 
coordination with the other department, an annual summary report that describes the impact of the 
risk adjustment program on premium rates in the state. The bill would also require the reports to 
be posted on the departments’ respective public websites no later than seven months after the risk 
adjustment year. The federal Patient Protection and Affordable Care Act (PPACA), which enacted 
various health care coverage market reforms, requires a state, using criteria and methods developed 
by the United States Secretary of Health and Human Services, to implement a risk adjustment 
program under which a charge is assessed on low actuarial risk plans and a payment is made to 
high actuarial risk plans. This bill effectuates the federal legislation. [S. Health] 
SB 407 (Monning), as amended on March 28, 2019, would amend sections 1358.11 and 
1358.91 of the Health and Safety Code, to extend the Medicare supplement annual open enrollment 
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period 30 additional days (for a total of 60 days or more), commencing with the individual’s 
birthday. The bill eliminates a restriction that an individual may only purchase coverage during 
the annual open enrollment period under specified circumstances, and allowing an individual to 
choose any Medicare supplement coverage during the annual open enrollment period. Amended 
section 1358.91 would require an issuer of a Medicare supplemental contract with new or 
innovative benefits, which is advertised, solicited, or issued for delivery in California on or after 
January 1, 2020, to offer the new or innovative benefits only as a rider to the Medicare 
supplemental contract, thus creating guaranteed renewability for consumers. [S. Health] 
SB 784 (Pan), as introduced on March 7, 2019, would amend sections 1358.91 and 1358.11 
of, and add section 1358.92, to the Health and Safety Code, to make conforming changes in 
California law to the requirements and standards that apply to Medicare supplement contracts and 
policies, for the purpose of complying with the federal laws affecting contracts delivered or issued 
after January 1, 2020. This bill contains an urgency clause to ensure that the provisions of the bill 
go into immediate effect upon enactment. Supporters of this bill argue that it makes necessary 
amendments to California’s laws governing Medicare Supplement to protect seniors and ensure 
that the state maintains the ability to regulate this product. [S. Health] 
AB 1268 (Rodriguez), as introduced on February 21, 2019, would amend sections 1363.5 
and 1367.01 of the Health and Safety Code, to require a health care service plan that prospectively 
reviews and approves, modifies, delays, or denies services, based in whole or in part on medical 
necessity, to report to DMHC the number of times in the previous year the service was approved, 
modified, delayed, or denied. According to the author, “we cannot begin to address the problem 
[prior authorizations delaying necessary medical care] without information and facts, and this bill 
will ensure that the detailed data is collected and made available to stakeholders .…” [A. Health] 
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SB 260 (Hurtado), as amended on March 26, 2019, would amend section 1366.50 of the 
Health and Safety Code, relating to automatic health care coverage enrollment. Amended section 
1366.50 would require, no later than July 1, 2020, Covered California to use specified information 
to enroll an individual who was terminated from a health coverage program administered by the 
Department of Health Care Services, in the lowest cost silver plan available, or in the individual’s 
previous managed care plan before the termination date of Medi-Cal coverage, under specified 
circumstances. This bill would further require a health plan to annually notify an enrollee that 
when the enrollee terminates coverage that their contact information will be provided to Covered 
California to assist in obtaining other coverage, or that they may opt out of this transfer of 
information. [S. Appr] 
AB 1656 (Gallagher), as amended on March 21, 2019, would amend section 11217 of the 
Health and Safety Code, to clarify that a physician or authorized hospital staff may administer or 
dispense controlled substances in a hospital to maintain or detoxify a person related to medical or 
surgical treatment of conditions other than addiction, or to treat people with pain for which a 
significant relief or cure has not been possible after reasonable efforts. [A. Health] 
AB 290 (Wood), as amended on March 5, 2019, would add section 1367.016 to the Health 
and Safety Code, to institute requirements for third-party payments of health insurance premiums, 
and implement a prohibition on assistance that is conditioned on the use of a specific facility or 
provider. New section 1367.016 would require that third-party payers disclose payments to health 
plans and requires health plans to report this information to DMHC. According to the author, this 
bill addresses concerns that dialysis companies, through a third party, may be veering patients 
away from Medicare or Medi-Cal by indirectly paying a patient’s premiums, for the company’s 
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own financial benefit. This bill will still allow providers, like dialysis companies, to donate to 
nonprofit organizations if they want to help provide premium assistance to patients. [A. Appr] 
AB 648 (Nazarian), as amended on March 28, 2019, would add section 1367.13 to the 
Health and Safety Code, to establish rules that govern wellness programs instituted by health plans. 
New section 1357.13 would require a health plan to comply with data privacy protections, limit 
sharing of data and destroy data upon conclusion of the program, and provide clear written 
explanations about program parameters, data collection, and enrollee rights. [A. Appr]  
AB 1676 (Maienschein), as introduced on February 22, 2019, would add 1367.626 to the 
Health and Safety Code, to require that health plans and insurers, by January 1, 2021, establish a 
telehealth consultation program and maintain records surrounding certain patient’s telehealth 
mental health data. The bill requires a health plan or insurer to communicate information relating 
to the telehealth program and its availability to contracting medical providers who treat children 
and pregnant and postpartum persons, including pediatricians, obstetricians, and primary care 
providers, at least twice a year in writing. [A. Health] 
SB 746 (Bates), as introduced on February 22, 2019, would add 1367.667 to the Health 
and Safety Code, to require every health plan contract and health insurance policy issued, 
amended, or renewed in California on or after January 1, 2020, that provides coverage for 
chemotherapy or radiation therapy for the treatment of cancer, to also provide coverage for 
anticancer medical devices. [S. Health] 
AB 993 (Nazarian), as amended on April 11, 2019, would add 1367.693 to the Health and 
Safety Code, to require that if the HIV specialist meets the plan’s criteria, then the health plan must 
allow an HIV specialist who is a physician, physician assistant, or nurse practitioner to be eligible 
as a primary care provider. According to the author, “Californians living with HIV should have 
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access to care from physicians and other providers with the training and experience required to 
meet their complex needs.” [A. Appr] 
AB 598 (Bloom), as introduced on February 14, 2019, would add 1367.72 to the Health 
and Safety Code, to require a health plan to include overage for hearing aids for an enrollee who 
is under the age of 18 years. [A. Health] 
SB 382 (Nielsen and Stern), as amended on March 26, 2019, would add section 1368.7 to 
the Health and Safety Code, to require a health care service plan contract or health insurance policy 
entered into, amended, or renewed on or after January 1, 2020, to provide reimbursement for care 
provided to enrollees who remain in acute care hospitals, and no longer meet the medical necessity 
criteria for care in an acute care hospital, due to a lack of access to post-acute care services during 
a state of emergency. This bill would require daily reimbursement rates to be no lower than the 
Medi-Cal administrative day rate, unless the plan or insurer has otherwise contracted with the acute 
care hospital for reimbursement during a state of emergency. According to the author, “[i]n order 
to avoid leaving patients in limbo regarding their health care coverage and questions about access 
during an emergency, this bill would ensure that individuals and families with health insurance 
can access health care regardless of availability of services outside of an acute care facility.” [S. 
Health] 
LITIGATION 
Pharmaceutical Research & Manufacturers of America v. Brown, Case No. 2:17-cv-
02573-MCE-KJN (E.D. Cal.). On October 26, 2018, on the Court’s own motion and pursuant to 
Local Rule 230(g), U.S. District Judge Morrison C. England, Jr. of the Eastern District of 
California vacated the December 13, 2018, hearing on Defendant’s Motion to Dismiss without 
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appearance and argument. (This case involves the constitutionality of SB 17 (Hernandez) (Chapter 
603, Statutes of 2017), a bill challenged by Petitioner PhRMA in this lawsuit, which attempts to 
provide transparency in regard to prescription drug pricing, including requiring drug 
manufacturers to provide advance information on and a justification for prescription drug price 
increases.) The order also provided that the opposition or statement of non-opposition and reply 
shall be filed in accordance with the original motion hearing date and, if the court determines that 
oral argument is needed, it will be scheduled at a later date. To date, oral argument has not been 
scheduled. At this writing, motions and responses have been submitted by both parties and are 
pending.  
As reported previously, on September 28, 2018, Petitioner PhRMA submitted its first 
amended complaint. PhRMA alleges that SB 17 is unconstitutional in that it compels them to speak 
about potential price increases when they would prefer not to communicate that information (thus 
violating these corporation’s asserted first amendment rights); additionally, PhRMA alleges that 
the bill interferes with interstate commerce. In its prayer for relief, PhRMA seeks an injunction to 
prevent California from implementing and enforcing SB 17, and a declaration that the statute is 
unconstitutional. [24:1 CRLR 44–45]  
Other pharmaceutical companies have followed PhRMA’s lead and filed lawsuits to 
prevent the enforcement of SB 17. On December 11, 2018, Petitioner Amgen Inc., filed a Petition 
for Writ of Mandate and declaratory and injunctive relief in superior court to prevent disclosure of 
its confidential, proprietary, and trade secret drug pricing information that it was required to 
provide to the California Correctional Health Care Services (CCHCS) in Amgen Inc. v. The 
California Correctional Health Care Services, No. 18STCP03147 (Super. Ct. Los Angeles). 
According to the petition, in November and December 2018, CCHCS, informed Amgen that it had 
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received Californian Public Records Act (CPRA) requests for the potential price changes that 
Amgen had provided to the agency. According to Amgen’s petition, SB 17 does not require drug 
manufacturers to publicly disclose potential increases in drug prices, nor does it modify the CPRA 
in any way. 
On February 1, 2019, after consideration of the parties’ briefs and argument, in an eight-
page order (the “PI Order”), the court granted Amgen’s preliminary injunction motion and ordered 
that Amgen’s SB 17 notice should not be disclosed pursuant to a CPRA request until Petitioner 
effectuates a price increase for the medications in the notice. At this writing, Defendant CCHCS’s 
appeal is pending.  
A similar ruling was also granted in Ipsen Biopharmaceuticals, Inc. v. California Public 
Employees’ Retirement System, et al., No. CPF-18-516445 (Super. Ct. San Francisco). On 
December 13, 2018, the superior court judge granted Ipsen Biopharmaceuticals, Inc.’s order to 
show cause and temporary restraining order against defendants The California Public Employees’ 
Retirement System (CalPERS), and the California Correctional Health Care Services (CCHCS). 
CalPERS and CCHCS are ordered to show cause why a preliminary injunction should not be 
ordered, pending trial in this action, restraining and enjoining defendants from disclosing the 
content of any Ipsen confidential pricing information submitted in accordance with the section 
127677 of the Health and Safety Code, as responsive to the CPRA request received or to be 
received requesting such information. 
On February 27, 2019, the court issued an order on joint stipulation regarding stay of 
proceedings in this action.  The court stated that there is “substantial overlap between the claims, 
issues, and parties involved in this case and the Los Angeles litigation (Amgen Inc. v. The 
California Correctional Health Care Services); and therefore, the outcome of proceedings relating 
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to the preliminary injunction motion in the Los Angeles case will affect the scope and conduct of 
this case. According to the order, the parties stipulate and agree that all proceedings in this 
litigation shall be stayed while the preliminary injunction in the Los Angeles litigation remains in 
effect and the stay will automatically expire if the preliminary injunction in the Los Angeles 
litigation is terminated. The order also stipulates, in the event that an order issued terminates the 
preliminary injunction in the Los Angeles litigation, CalPERS and CCHCS shall continue to 
withhold Ipsen’s allegedly confidential and proprietary information for a period of 21 days from 
the issuance of the order. If Ipsen moves for a preliminary injunction during that 21-day period, 
CalPERS and CCHCS shall continue to withhold Ipsen’s allegedly confidential and proprietary 
information until a ruling on that motion is issued. 
Not all parties requesting preliminary injunctions against agencies are being granted so 
quickly. On October 26, 2018, the Plaintiffs’ motion for preliminary injunction was heard and 
taken under advisement in Association for Community Affiliated Plans, et al. v. United States 
Department of Treasury, et al., Case No. 1:18-cv-02133-RJL (D.D.C.).  The court stated that it 
would not be possible to complete an opinion in this case within a few weeks because it’s too 
complicated, too large, and too consequential, and then the court went into recess. 
On November 12, 2018, upon consideration of Plaintiffs’ notice of withdrawal of motion 
for a preliminary injunction and motion for expedited briefing schedule, and defendants’ response, 
the court ordered a hearing on the parties’ cross-motions for summary judgment to be held on 
February 19, 2019. However, on December 31, 2018, Judge Richard J. Leon granted the 
Defendants’ motion to stay proceedings in light of a lapse of appropriations to the Department of 
Justice. On March 1, 2019, Judge Leon ordered that the stay in this case be lifted and Defendants’ 
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motion to modify the briefing schedule be granted. At this writing, all parties and numerous amici 
curiae are briefing the case; no further arguments have been held. 
Update on Federal Government Actions  
♦ Texas, et al. v. United States of America, 300 F. Supp. 3d 810 (2019). In Texas v. United 
States of America, twenty Republican state attorneys general and two individual plaintiffs 
challenged the constitutionality of the individual mandate and with it, the entire Affordable Care 
Act (ACA). The states brought an action alleging that the United States, United States Department 
of Health and Human Services (HHS), HHS Secretary, Internal Revenue Service (IRS), and its 
Commissioner, effectively required states to pay Health Insurance Providers Fees (HIPF) imposed 
by the ACA in order to receive Medicaid funds, thus, violated the vesting clause, the 
Administrative Procedure Act (APA), and the spending clause. Plaintiffs sought declaratory 
judgment and a permanent injunction to prevent the defendants from prospectively collecting the 
provider fees. The parties in the action filed cross-motions for summary judgment.  
On March 5, 2019, Judge Reed O’Connor held that the ACA is unconstitutional. The ruling 
is currently being appealed and several stakeholders have been filing amicus briefs during the past 
several months, including The National Women’s Law Center, National Partnership for Women 
and Families, and the Black Women’s Health Initiative. 
♦ State of New York, et al. v. U.S. Department of Labor, Civ. Action No. 18-1747, 
(D.D.C.). The following is a status update on State of New York, et al. v. U.S. Department of Labor 
has been covered previously in Volume 24, No. 1 (Fall 2018) of the California Regulatory Law 
Reporter [24:1 CRLR 46]:  
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On March 28, 2019, United States District Judge Bates entered an order granting the 
motion for summary judgment for the plaintiff and denying motion for summary judgement and 
motion to dismiss for the defendant. On August 23, 2018, Plaintiffs filed a memorandum of law in 
support of a motion for summary for judgment. Plaintiffs argue that the administration is violating 
the ACA’s purpose of establishing minimum insurance protections. Defendants filed a counter 
memorandum of law in support of their position for summary judgment in conjunction with a 
motion to dismiss. In defendant’s memorandum for summary judgement it is argued that loosening 
of health plans allows for more affordable health care, and more covered Americans.  
On July 26, 2018, the complaint was filed by 12 state attorneys general entitled State of 
New York, et al. v. U.S. Department of Labor, in the U.S. District Court for the District of 
Columbia. This complaint challenges the Trump administration’s regulation issued this year that 
makes it easier for individuals and small employers to band together to purchase health care 
coverage through association health plans (AHPs) that do not meet ACA standards.  
